Exubera Gone, But Not Forgotten: FDA Imposes REMS, Mandates Trials

Pfizer is no longer marketing inhaled insulin, but the regulatory work continues. FDA makes clear that any future inhaled insulin products will need a risk management plan and mandatory post-marketing studies.